Detalhe da pesquisa
1.
Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients.
Cell;
185(3): 563-575.e11, 2022 02 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35120664
2.
Neoadjuvant relatlimab and nivolumab in resectable melanoma.
Nature;
611(7934): 155-160, 2022 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36289334
3.
Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma.
N Engl J Med;
389(24): 2256-2266, 2023 Dec 14.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37870955
4.
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma.
N Engl J Med;
385(13): 1196-1206, 2021 09 23.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34551229
5.
Author Correction: Neoadjuvant relatlimab and nivolumab in resectable melanoma.
Nature;
615(7953): E23, 2023 Mar.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36894629
6.
Determinants of overall survival in patients with metastatic uveal melanoma.
Cancer;
129(20): 3275-3286, 2023 10 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37382208
7.
Decision-Making and Health-Related Quality of Life in Patients with Melanoma Considering Adjuvant Immunotherapy.
Oncologist;
28(4): 351-357, 2023 04 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36745014
8.
Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival.
Cancer Immunol Immunother;
72(4): 945-954, 2023 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36197494
9.
Undifferentiated and Dedifferentiated Metastatic Melanomas Masquerading as Soft Tissue Sarcomas: Mutational Signature Analysis and Immunotherapy Response.
Mod Pathol;
36(8): 100165, 2023 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36990277
10.
Clinical and genomic correlates of imatinib response in melanomas with KIT alterations.
Br J Cancer;
127(9): 1726-1732, 2022 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35999272
11.
Benefit and toxicity of programmed death-1 blockade vary by ethnicity in patients with advanced melanoma: an international multicentre observational study.
Br J Dermatol;
187(3): 401-410, 2022 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35293617
12.
Anorectal Mucosal Melanoma in the Era of Immune Checkpoint Inhibition: Should We Change Our Surgical Management Paradigm?
Dis Colon Rectum;
64(5): 555-562, 2021 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33939387
13.
Lung-only melanoma: UV mutational signature supports origin from occult cutaneous primaries and argues against the concept of primary pulmonary melanoma.
Mod Pathol;
33(11): 2244-2255, 2020 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32581366
14.
Survival Outcomes After Metastasectomy in Melanoma Patients Categorized by Response to Checkpoint Blockade.
Ann Surg Oncol;
27(4): 1180-1188, 2020 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31848819
15.
DCE-MRI perfusion predicts pseudoprogression in metastatic melanoma treated with immunotherapy.
J Neurooncol;
146(2): 339-346, 2020 Jan.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31873875
16.
Isolated Abducens Nerve Palsy Following Pembrolizumab.
Neuroophthalmology;
44(3): 182-185, 2020 Jun.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32395170
17.
Tolerance and efficacy of BRAF plus MEK inhibition in patients with melanoma who previously have received programmed cell death protein 1-based therapy.
Cancer;
125(6): 884-891, 2019 03 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30521084
18.
Myocarditis Surveillance in Patients with Advanced Melanoma on Combination Immune Checkpoint Inhibitor Therapy: The Memorial Sloan Kettering Cancer Center Experience.
Oncologist;
24(5): e196-e197, 2019 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30910868
19.
A phase Ib study of BGJ398, a pan-FGFR kinase inhibitor in combination with imatinib in patients with advanced gastrointestinal stromal tumor.
Invest New Drugs;
37(2): 282-290, 2019 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30101387
20.
Correction to: Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival.
Cancer Immunol Immunother;
72(4): 955, 2023 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36538061